Store in a cool, dry place below 30C. Protect from light and moisture.
Tablet Marking
DUOVIR N imprint
Controlled Substance
No
Country of License
India
Contraindications
Hypersensitivity to any of the components
Product Code
DUOVIRN60
Regulatory Approvals
DCGI (Drugs Controller General of India) approved
Side Effects
May cause rash, nausea, headache, fatigue, anemia, liver dysfunction
Intended Market
Global; especially developing countries with high HIV prevalence
Administration Route
Oral
Color
White
Prescription Status
Prescription only
Shape
Capsule-shaped Tablets
WHO Prequalified
Yes
Patient Population
Not recommended for children under 12 years
Duovir N Lamivudine Zidovudine and Nevirapine Tablets Trade Information
Minimum Order Quantity
10 Pieces
Supply Ability
1000 Pieces Per Month
Delivery Time
7 Days
About Duovir N Lamivudine Zidovudine and Nevirapine Tablets
Packaging Size
60 Tablets/ Bottle
Manufacturer
Cipla
Brand
Duovir N
Packaging Type
Box
Salt
Lamivudine Zidovudine and Nevirapine
Treatment
To Treat HIV to manage or Treat AIDS
Duovir-N is an antiretroviral formulation manufactured by Cipla Limited, an award-winning Indian pharmaceutical company. The medicine effectively manages human immunodeficiency virus (HIV) infections, with each tablet containing 150mg of lamivudine, 300mg of zidovudine, and 200mg of nevirapine.